Deproteynyzyrovann y hemoderyvat blood of lambs | Actovegin injection for 40 mg / pc ampoules 10 ml.

Latin name

ACTOVEGIN

Release form

Injection solution is clear, yellowish, practically free of particles.

Packing

10 ml - clear glass ampoules (5) - contour plastic cell packaging (1) - packs of cardboard.

Pharmacological action

antihypoxant. Actovegin is a hemoderivative, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass).

Positive effect on the transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of the plasma membranes of cells during ischemia and a decrease in the formation of lactates), thus possessing an antihypoxic effect that begins to manifest itself at the latest 30 minutes (10-30 minutes) after parenteral administration and reaches a maximum and average after 3 hours (2-6 hours).

Actovegin increases the concentration of ATP, LDF, phosphocreatine, as well as amino acids - glutamate, aspartate and GABA.

The use of Actovegin to accelerate wound healing is also based on the above data. Moreover, not only morphological, but also the biochemical parameters of granulation - increased DNA concentration. hemoglobin and hydroxyproline.

Indications

metabolic and vascular disorders of the brain (including ischemic stroke, traumatic brain injury)

peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers)

healing of various wounds (ulcers , burns, trophic disorders (bedsores), impaired wound healing processes)

prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy.

Contraindications

hypersensitivity to Actovegin® or similar drugs

decompensated heart failure

pulmonary edema

oliguria, anuria

fluid retention.

Precautions: hyperchloremia, hypernatremia.

Use during pregnancy and lactation

Use of the drug in pregnant women did not cause a negative effect on the mother or fetus.

However, when used in pregnant women, the potential risk to the fetus must be considered.

Composition of

1 ampoule contains:

active substance:

Actovegin® concentrate (in terms of dry deproteinized hemoderivative of calf blood) 1) - 400.0 mg

excipient:

water for injection - up to 10 ml.

1) Actovegin® concentrate contains sodium chloride in the form of sodium and chlorine ions, which are components of calf blood.

Sodium chloride is not added or removed during the production of the concentrate.

The sodium chloride content is about 53.6 mg (for 2 ml ampoules), about 134.0 mg (for 5 ml ampoules) and about 268.0 mg (for 10 ml ampoules).

Dosage and administration of

V / a, iv (including as infusion) and / m. In connection with the potential for the development of anaphylactic reactions, it is recommended to conduct a test before the start of the infusion.

Depending on the severity of the clinical picture, 10-20 ml / day iv or iv and then 5 ml iv or 5 ml iv.

When administered in the form of infusion to 200-300 ml of the main solution (0, 9% sodium chloride solution or 5% dextrose solution) add 10-20 ml of Actovegin®. Speed ​​of administration: about 2 ml / min.

Metabolic and vascular disorders of the brain: at the beginning of treatment, 10 ml iv daily for two weeks, then 5-10 ml iv 3–4 times a week for at least 2 weeks.

Ischemic stroke: 20-50 ml in 200-300 ml of the main solution in / drip daily for 1 week, then 10 - 20 ml in / drip 2 weeks.

Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml of the drug in 200 ml of the main solution in / a or iv daily treatment duration of about 4 weeks.

Wound healing: 10 ml iv or 5 ml iv daily or 3-4 times a week, depending on the healing process (in addition to local treatment with Actovegin® in topical dosage forms).

Prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy: the average dose is 5 ml iv daily during breaks of radiation exposure.

Radiation cystitis: daily 10 ml transurethrally in combination with antibiotic therapy.

Side effects

Allergic reactions (skin rash, hyperemia of the skin, hyperthermia) up to anaphylactic shock.

Drug Interaction

Currently unknown.

Storage conditions

At a temperature not exceeding 25 РC in a dark place.

Keep out of the reach and sight of children!

Shelf life

3 years. Do not use after expiration date.

Deystvuyushtee substance

Deproteinizirovann y gemoderivat Resurrection facturer

Terms and conditions

prescription

dosage form

injection

Prescription

Prescription

For I am an adult as prescribed by a doctor, Pregnant as prescribed by a doctor

Takeda GmbH, Russia